 |
 |
|
 |
|
|
- DEC 15, 2006: Bradmer Pharmaceuticals Meets with FDA on Initiation of Phase III Trial for Neuradiab
- NOV 28, 2006: Bradmer Pharmaceuticals Contracts With Prologue Research to Manage Multi-Center Pivotal Trial of Neuradiab in Brain Cancer
- NOV 9, 2006: Bradmer Pharmaceuticals Announces 2006 Third-Quarter Operational and Financial Results
- NOV 2, 2006: Bradmer Pharmaceuticals Granted Orphan Drug Designation for Neuradiab by European Medicines Agency
- OCT 31, 2006: Bradmer Pharmaceuticals to Present at Rodman & Renshaw Healthcare Conference
- SEP 25, 2006: Bradmer Pharmaceuticals Announces Hiring of Dr. Alan M. Ezrin, Chief Operating Officer
- SEP 5, 2006: Bradmer Pharmaceuticals to Present at ThinkEquity Partners Growth Conference
- AUG 10, 2006: Bradmer Pharmaceuticals Announces 2006 Second-Quarter Operational and Financial Results
- JUN 6, 2006: Bradmer Pharmaceuticals Extends Patent Portfolio with Allowance Letter from European Patent Office
- MAY 12, 2006: Bradmer Pharmaceuticals Announces 2006 First-Quarter Operational and Financial Results
- APR 20, 2006: Bradmer Pharmaceuticals Announces 2005 Year-End Operational and Financial Results
- APR 19, 2006: Bradmer Pharmaceuticals Completes Supply Agreement with MDS Nordion
- APR 18, 2006: Bradmer Pharmaceuticals to Commence Trading on Toronto Stock Exchange
- MAR 31, 2006: Bradmer Pharmaceuticals Plans to List on Toronto Stock Exchange
- MAR 17, 2006: Bradmer Pharmaceuticals Announces Board Committees
- MAR 2, 2006: Bradmer Pharmaceuticals Completes Manufacturing Agreement with Laureate Pharma
- FEB 15, 2006: Bradmer Pharmaceuticals Receives Final Approval For Qualifying Transaction
- FEB 10, 2006: Bradmer Pharmaceuticals Completes Qualifying Transaction
- JAN 10, 2006: Bradmer Pharmaceuticals Enters Amalgamation Agreement with Blue Devil Pharmaceuticals
- JAN 4, 2006: Bradmer Pharmaceuticals Raises $15 Million Under Offerings
 * Note: Links will open in PDF format
Readers are advised that information posted to the Bradmer Pharmaceuticals website was deemed accurate at the time it was posted, but may be superseded by subsequent disclosures.
|
|
|
|
|
|
